Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 20.1 CHF -3.13% Market Closed
Market Cap: 755.2m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Kuros Biosciences AG
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kuros Biosciences AG
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Kuros Biosciences AG
SIX:KURN
Other Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Other Liabilities
$19.1m
CAGR 3-Years
-43%
CAGR 5-Years
57%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Other Liabilities
CHf10.7m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Other Liabilities
$226.7m
CAGR 3-Years
2%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Other Liabilities
CHf1.9m
CAGR 3-Years
-42%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Other Liabilities
CHf38.4m
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
-13%
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
739m CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
5.91 CHF
Overvaluation 71%
Intrinsic Value
Price

See Also

Back to Top